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CLIP-related methodologies and their 
application to retrovirology
Paul D. Bieniasz1 and Sebla B. Kutluay2* 
Abstract 
Virtually every step of HIV-1 replication and numerous cellular antiviral defense mechanisms are regulated by the 
binding of a viral or cellular RNA-binding protein (RBP) to distinct sequence or structural elements on HIV-1 RNAs. 
Until recently, these protein–RNA interactions were studied largely by in vitro binding assays complemented with 
genetics approaches. However, these methods are highly limited in the identification of the relevant targets of RBPs in 
physiologically relevant settings. Development of crosslinking-immunoprecipitation sequencing (CLIP) methodology 
has revolutionized the analysis of protein–nucleic acid complexes. CLIP combines immunoprecipitation of covalently 
crosslinked protein–RNA complexes with high-throughput sequencing, providing a global account of RNA sequences 
bound by a RBP of interest in cells (or virions) at near-nucleotide resolution. Numerous variants of the CLIP protocol 
have recently been developed, some with major improvements over the original. Herein, we briefly review these 
methodologies and give examples of how CLIP has been successfully applied to retrovirology research.
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(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
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and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/
publi cdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Following the integration of proviral DNA into the host 
cell chromosome, genesis of new HIV-1 particles is ini-
tiated by the host RNA Polymerase II-mediated synthe-
sis of a single poly-cistronic viral RNA species [1]. This 
transcript undergoes varying levels of alternative splic-
ing generating over 40 different RNA species, an event 
orchestrated by the host cellular splicing machinery and 
cis-acting elements on viral RNAs [1, 2]. Like cellular 
mRNAs, all viral RNAs contain 5′ 7-methylguanosine 
(m7G) caps and 3′ polyA tails [1, 3]. While fully spliced 
viral RNAs can exit the nucleus via canonical nuclear 
export pathways, the partially spliced and unspliced viral 
RNAs depend on the viral Rev and cellular Crm1 proteins 
for nuclear export [4]. All viral mRNAs are subsequently 
translated in the cytosol, but the unspliced full-length 
viral RNAs also serve as the viral genome and are pack-
aged into virions by the viral major structural protein 
Gag. Following their release from the plasma membrane, 
particles undergo a maturation step triggered by the viral 
protease enzyme. During this process, Gag and Gag-Pol 
proteins are cleaved into their constituent domains, the 
CA domain of Gag forms a conical lattice and the viral 
RNA genome condenses with the cleaved NC domain 
of Gag and viral enzymes inside this conical core [5, 6]. 
Thus, virtually every step in HIV-1 replication depends 
on a complex and changing set of interactions between 
viral RNAs and the multitude of trans-acting viral and 
cellular RNA-binding proteins. Historically, the interac-
tions between these proteins and their RNA targets have 
largely been mapped by genetic studies, complemented 
by limited in  vitro approaches. Comprehensive analysis 
of these interactions in physiologically relevant settings 
was effectively impossible prior to the recent develop-
ment of cutting-edge next-generation sequencing-based 
methodologies. These methods, collectively referred to 
as CLIP (crosslinking-immunoprecipitation coupled with 
next-generation sequencing), allow the global identifica-
tion of RNA targets of RNA-binding proteins (RBPs) in 
physiological settings in unprecedented detail. In this 
review, we provide a detailed outline of the existing 
CLIP methodologies, discuss their advantages and short-
comings (based partly on our own experience) and give 
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Principles of CLIP and variant methodologies
In simple terms, CLIP is a powerful methodology with 
which one can identify the RNA targets of RNA-binding 
proteins in physiological settings, ranging from live cells 
to virus particles and even animal tissues. The inception 
of the original CLIP protocol [7, 8] and its subsequent 
coupling to next-generation sequencing [9] has revolu-
tionized the study of protein–RNA interactions. Since 
then, several other versions of CLIP have been developed. 
The salient steps of the existing CLIP methodologies 
are (Fig.  1): (1)  protein–RNA complexes are covalently 
crosslinked in live cells/tissues/virions; (2) Cells/tissues/
virions are lysed and treated with limited amounts of 
RNases leaving small fragments of RNA molecules (~ 20 
to 50 nucleotides) protected by the protein of interest; (3) 
Protein–RNA complexes are immunoprecipitated, and 
non-specific RNAs and proteins are removed by strin-
gent washes. Because the protein–RNA complexes are 
covalently crosslinked, these stringent conditions, in 
principle, do not affect purification of target protein–
RNA adducts. (4) The purified protein–RNA complexes 
are radioactively labeled and separated by SDS-PAGE. (5) 
Bound RNA is isolated either directly from SDS-PAGE 
gels or from nitrocellulose membranes following transfer 
by Proteinase K treatment. (6)  Eluted RNA is ligated to 
adapters, reverse transcribed, the resulting cDNA is PCR 
amplified and subjected to sequencing. (7)  Sequencing 
reads are processed and mapped to reference genomes. 
Depending on the method used, the resulting library 
contains nucleotide substitutions or deletions at the site 
of crosslinking, which allows mapping of the site of pro-
tein–RNA interactions at near-nucleotide resolution. 
Subsequent analyses include determination of the signifi-
cantly enriched binding sites, identification of the bind-
ing motifs within them as well as other custom analyses. 
In the remainder of this section we will review the cur-
rently existing CLIP methods and give an overview of the 
widely used CLIP data analysis tools and pipelines.
HITS‑CLIP
Historically, protein–RNA interactions were studied 
largely using in  vitro binding assays with pure proteins 
and RNAs. Alternatively, GST-pulldown and immuno-
precipitation-based assays were conducted on cell lysates 
followed by downstream quantitative analysis of RNA by 
Q-RT-PCR or microarrays. A major drawback of these 
cell lysate-based approaches was their limited ability to 
identify direct interactions between a RBP and its target 
RNA molecules. Their limited power was due at least in 
part to the presence of contaminating protein and RNA 
molecules in the isolated RBP-RNA complexes. Devel-
opment of the original CLIP protocol [7, 8], in which the 
protein–RNA complexes were UV-crosslinked in  vivo 
and immunoprecipitated under stringent conditions to 
remove the contaminating proteins and RNA molecules 
marked the first advancement over these traditional 
methods. While the initial CLIP methodology relied on 
cloning and subsequent sequencing of the RNA targets, 
the coupling of CLIP to high-throughput sequencing, 
HITS-CLIP, allowed global transcriptome-wide analy-
sis of RBP-RNA crosslinks [9]. HITS-CLIP relies on UV 
crosslinking of protein–RNA complexes at UV254  nm. 
As such, HITS-CLIP can be applied to animal tissues 
due to its high level of penetration. Following crosslink-
ing and immunoprecipitation of protein–RNA com-
plexes, ligation to the radioactively labeled 5′ adapter is 
performed while the protein–RNA adducts are attached 
to beads. This allows the removal of unligated 5′ adapter 
by further rounds of bead washing, which substantially 
reduces the appearance of adapter–adapter ligation 
products following downstream processing. The isolated 
protein–RNA adducts are separated by SDS-PAGE and 
transferred to nitrocellulose membranes. As naked RNA 
molecules are not retained on the nitrocellulose mem-
branes, protein–RNA complexes are purified further 
during this step. Transfer to nitrocellulose membranes 
has been utilized in other CLIP approaches and in our 
experience confers a major advantage over the originally 
described PAR-CLIP approach described below. Pro-
tein-crosslinked RNA is further purified from nitrocel-
lulose membranes by proteinase K treatment, ligated to 
the 3′ adapters and PCR-amplified prior to sequencing. 
Detailed bioinformatics analyses of HITS-CLIP datasets 
revealed that reverse transcriptase (RT) introduces dele-
tions at the site of crosslinking [10], albeit at a fairly low 
frequency, allowing HITS-CLIP to reach to near nucleo-
tide-resolution identification of binding sites.
PAR‑CLIP
A major advantage of PAR-CLIP [11] over HITS-CLIP is 
the use of ribonucleoside analogs, including 4-thiouri-
dine (4SU) and 6-thioguanosine (6SG), that significantly 
enhance the efficiency of protein–RNA crosslinking. In 
PAR-CLIP experiments, cells are typically grown in the 
presence of ribonucleoside analogs for up to 16  h and 
UV-crosslinked at a longer wavelength (365  nm). As 
such, in contrast to HITS-CLIP, application of PAR-CLIP 
is largely limited to cell culture systems (an exception 
(See figure on next page.)
Fig. 1 Outline of CLIP
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being C. elegans which can be grown in 4SU containing 
media and efficiently UV-crosslinked due to its transpar-
ency [12]). Although the original PAR-CLIP description 
utilized an inducible tagged RNA-binding protein [11], 
we and many other groups have successfully adapted 
PAR-CLIP to study endogenous proteins, including 
HIV-1 NC and IN [13, 14], Argonaute [15–18], as well as 
other proteins involved in RNA biogenesis and metabo-
lism [19–24]. A potential disadvantage of the PAR-CLIP 
protocol is the cellular toxicity that may be induced by 
4SU treatment depending on the cell type, the dose and 
incubation time [25]. Thus, optimal conditions that allow 
efficient protein–RNA crosslinking without major toxic-
ity should be determined on a case-by-case basis. Never-
theless, PAR-CLIP allows accurate nucleotide resolution 
mapping of target RNA sites due to mutations introduced 
by RT (T-to-C for 4SU and G-to-A for 6SG) precisely at 
the site of crosslinking during cDNA synthesis. While 
allowing nucleotide resolution mapping, use of ribonu-
cleoside analogs may inadvertently enrich RNA elements 
with distinct nucleotide composition or alter RNA struc-
ture [26], which may subsequently affect protein binding. 
Careful validation of PAR-CLIP experiments with differ-
ent ribonucleoside analogs and RNases should, in princi-
ple, address these potential problems.
iCLIP
Identification of the precise crosslinking site in the HITS-
CLIP and PAR-CLIP approaches relies respectively on 
deletions and substitutions introduced by RT during 
cDNA synthesis. However, read-through at crosslinking 
sites appears to be a relatively rare event as compared to 
truncations that occur as a result of RT stalling at these 
sites [27, 28]. Thus, a major shortcoming of HITS-CLIP 
and PAR-CLIP approaches is the loss of a large fraction 
(estimated to be > 80%) of the starting material due to 
the inability to recover truncated reverse transcription 
products. iCLIP [29] has been designed to address this 
problem by ligation of a 3′ adapter while protein–RNA 
complexes are still on beads followed by introduction of 
a two-part cleavable adaptor into cDNA during reverse 
transcription. The resulting cDNA is circularized and 
subsequently linearized with a restriction enzyme, which 
allows the recovery of a larger fraction of truncated 
cDNAs. In addition, as circularization is done at high 
temperatures, structured cDNA molecules are recovered 
at a much higher efficiency. As a result of this enrichment, 
iCLIP can yield higher complexity libraries and has been 
proposed to perform better than previous approaches in 
identification of the precise site of crosslinking [28–30]. 
Application of iCLIP on a large scale by the ENCODE 
consortium indicated that the success rate in generating 
libraries was low for many RBPs, which was ascribed to 
the low efficiency of the circularization step [31]. How-
ever, several studies that utilized iCLIP have generated 
libraries with sufficiently high complexity and sensitivity, 
and these parameters were not carefully assessed by the 
ENCODE consortium. The remainder of the iCLIP pro-
tocol is similar to HITS-CLIP and PAR-CLIP approaches. 
BrdU-CLIP [32] and FAST-iCLIP [33] are iterations of 
the iCLIP protocol, which provide alternative cDNA and 
RNA purification methods, respectively. For example, by 
exchanging the 3′ ddC blocker from the standard iCLIP 
3′ adaptor with a 3′ biotin moiety and subsequent purifi-
cation of ligation products on streptavidin beads, FAST-
iCLIP is reported to reduce the time required to perform 
iCLIP by 50%.
eCLIP
The eCLIP protocol [31] proposes to address some of the 
shortcomings of previous CLIP approaches by including 
two separate adapter ligation steps (i.e. in the HITS-CLIP 
and PAR-CLIP protocols). In eCLIP, the immunoprecipi-
tated RNA is first ligated to an indexed 3′ RNA adapter 
while complexes are still on the immunoprecipitation 
beads, and to a 3′ single-stranded (ss) DNA adapter after 
reverse transcription. As reverse transcription frequently 
terminates at the RBP-RNA crosslinking site, the ligation 
of the 3′ ssDNA adapter to the terminated cDNA frag-
ments allows higher recovery rates of the starting mate-
rial and helps in identification of the binding sites as in 
iCLIP. In addition, as the first 3′ RNA adapter already 
contains the indeces, samples can be combined at an 
earlier stage than in other protocols saving processing 
time. While adapter ligations conducted on beads has 
been inefficient in our hands (see below), the authors 
suggest that increased T4 RNA ligase concentration and 
the addition of high concentrations of polyethylene gly-
col (PEG8000) and DMSO in ligation reactions enable 
ligation efficiencies of up to > 90% [31]. In addition, RNA 
radiolabeling and autoradiographic visualization steps 
can be omitted allowing even faster library preparation 
times. However, these steps in our experience are highly 
important to purify the target protein–RNA complexes 
away from other proteins and RNA molecules that have 
non-specifically immunoprecipitated. Thus, the specific-
ity of eCLIP libraries should be carefully evaluated, as 
also reviewed by a recent study [34]. Finally, inclusion of 
a size-matched input control (SMInput) in eCLIP ena-
bles efficient background normalization and controls for 
any inherent biases in library generation. The remainder 
of the eCLIP protocol shares many of the same steps as 
other CLIP approaches, in particular iCLIP.
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irCLIP
Similar to eCLIP, irCLIP has been developed to overcome 
some of the shortcomings of previous CLIP methodolo-
gies by simplifying the library generation steps, increas-
ing the yield and complexity of the CLIP library, and 
allowing faster processing times. One of the major dif-
ferences of this approach is the utilization of a 3′ adapter 
conjugated to an infrared fluorescent dye [35], which 
provides a more sensitive and faster way of tracking the 
target RNA molecules compared to radioactive labeling. 
Similar to FAST-iCLIP, the adapter ligated RNA library is 
purified by streptavidin beads. CLIP has an inherent bias 
against identification of protein binding events on struc-
tured RNA elements due to stalling of RT at these sites. 
Although not proven, irCLIP may mitigate this problem 
by utilizing thermostable enzymes for circularization and 
reverse transcription steps to take place at 60  °C, which 
helps to resolve potential RNA secondary structures [35]. 
Other aspects of the irCLIP protocol, such as on-bead 
nuclease digestions and Proteinase K digestion in SDS 
have previously been utilized within the context of PAR-
CLIP experiments [11, 14]. As in iCLIP and eCLIP, the 
irCLIP procedure achieves single-nucleotide resolution 
by recovery of truncated cDNAs after the reverse tran-
scription stage.
Customizing CLIP
The major shortcomings of all of the above CLIP 
approaches include technically challenging and labor-
intensive protocols, and loss of the starting material at 
several inefficient steps in the procedure. This problem is 
further exacerbated if the initial protein–RNA complexes 
are not abundant due to low levels of expression in cells 
(virions), low crosslinking or immunoprecipitation effi-
ciencies. These problems can often lead to a final library 
with insufficient complexity and enrichment of environ-
mental contaminating sequences. When we adapted the 
CLIP protocol to study HIV-1 Gag-RNA interactions 
[36], we took advantage of both HITS-CLIP and PAR-
CLIP protocols as detailed in [14]. In our experience, 
4-SU-mediated crosslinking yielded more abundant 
Gag-, MA- and NC-RNA complexes, that was critical for 
generating libraries with sufficient sequence diversity for 
successful sequencing. While the original PAR-CLIP pro-
tocol relied on electroelution of protein–RNA complexes 
from SDS-PAGE gels, we opted for transfer of protein–
RNA complexes to nitrocellulose membranes following 
SDS-PAGE (as in HITS-CLIP). As naked RNA oligonu-
cleotides are not immobilized on nitrocellulose mem-
branes, this step provides an added level of protein–RNA 
complex purification. While the HITS-CLIP and many 
other protocols call for ligation of adapters while the pro-
tein–RNA complexes are on beads, the PAR-CLIP library 
generation protocol  in solution was significantly more 
efficient in our hands with 3′ and 5′ adapter ligations 
routinely working at > 90 and 50% efficiency. Although 
seemingly more cumbersome, sequential ligation of 
adapters provides more control over monitoring the liga-
tion efficiency and substantially decreases contaminating 
adapter–adapter ligation products. Additionally, we have 
utilized barcoded and degenerate sequence containing 
adapters, which enabled us to combine multiple samples 
(typically up to eight) and distinguish between independ-
ent ligation versus PCR overamplification events, respec-
tively. Finally, due to some of the potential inherent biases 
of the PAR-CLIP approach discussed above, we typically 
validate our findings using different ribonucleosides (4SU 
vs. 6SG) and RNases (RNase A vs. RNase T1).
CLIP data analyses
CLIP data analyses can be summarized in four major 
steps: (1) pre-processing of sequencing reads. (2) map-
ping of reads to reference genomes, (3) subjecting 
mapped reads to cluster finding algorithms to define 
binding sites, (4) analysis of binding sites for enrichment 
of certain features including where within a gene body 
the binding site is located, presence of distinct motifs or 
nucleotide composition. Recently a few pipelines that can 
perform the majority of these steps have been developed 
and include the PARCLIPsuite [37], CLIPZ [38], CIMS 
[39] and CLIP-seq tools [40]. Below, we will go through 
some of the publicly available and most frequently used 
standalone tools that can be utilized for analyses of CLIP 
data sets. For a more detailed review of these tools and 
algorithms we refer the readers to detailed recent reviews 
[41–44]. Implementing many of these analysis pipelines 
requires some level of coding knowledge and familiarity 
with shell scripting.
1. Pre-processing of sequencing reads: The resulting 
CLIP libraries in all of the above protocols will con-
tain some form of 3′ and 5′ adaptors. In the major-
ity of cases, these adaptors contain barcodes and 
degenerate sequences  (N3–10), which allow multiplex-
ing and differentiating between independent ligation 
versus PCR overamplification events, respectively. In 
these circumstances, a typical pipeline will involve 
removing low quality reads, collapsing of raw reads 
into unique reads, demultiplexing samples, discard-
ing short reads (typically less than 15 nucleotides) 
and trimming the adaptors prior to mapping. One of 
the most commonly used tools is the FASTX_toolkit 
(http://hanno nlab.cshl.edu/fastx _toolk it/), which 
provides a number of functions to accomplish all of 
these steps. Other alternatives, with more limited 
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functions include Cutadapt [45], Trimmomatic [46], 
PRINSEQ [47] as well as custom scripts.
2. Mapping to reference genomes: The reads that pass 
the above filtering steps are mapped onto reference 
genomes or transcriptomes. The most commonly 
used mapping algorithms used for this task include 
Bowtie [48], Bowtie2 [49], STAR [50], Novoalign 
(http://www.novoc raft.com/produ cts/novoa lign/), 
RMAP [51], TopHat [52], GSnap [53], SOAP [54] 
and BWA [55], some with unique advantages over 
others depending on whether mapping is done on 
a genome versus transcriptome. The choice of algo-
rithm and the parameters for mapping will need to 
be finely tuned depending on which CLIP method-
ology is employed and the properties of the RBP of 
interest. For example, PAR-CLIP reads are expected 
to contain a number of T-to-C substitutions, and 
thus mismatches (typically ≤ 2 for reads between 15 
and 40 nucleotides) should be allowed during map-
ping. While all algorithms allow mapping with mis-
matches, not all can handle deletions, which arise as 
a result of  UV254 nm crosslinking in HITS-CLIP and 
related methods. For example while the original Bow-
tie algorithm did not allow gaps during alignment, 
Bowtie2 was developed to enable alignments with 
indels. Similarly, if mapping is done on transcrip-
tomes, alignment algorithms such as STAR, which 
allow higher accuracy and speed for mapping spliced 
transcripts should be preferred. However, mapping 
to the transcriptome will clearly lead to the exclu-
sion of reads derived from introns, which may con-
stitute the primary binding sites for various splicing 
regulatory proteins. Thus, a general strategy whereby 
CLIP reads are mapped first to the transcriptome and 
the remaining reads are mapped to the genome may 
work the best for proteins for which there is no infor-
mation on the types of targeted RNA molecules.
3. Peak calling: The next essential step in CLIP analy-
sis is identification of the true binding sites by what 
is often referred to as peak calling. In simple terms, 
peak calling is the process by which clusters of 
reads that map to distinct locations are separated 
from background reads that may stem from unspe-
cific binding events or contaminants during the 
CLIP procedure. Peaks are typically defined based 
on a number of variables such as read depth rela-
tive to surrounding regions, presence of expected 
and absence of unwanted mutations (as in the case 
of PAR-CLIP-based approaches) and peak shape. 
While peak calling can be based solely on CLIP data, 
additional controls such as data derived from repli-
cates and negative controls (i.e. immunoprecipita-
tions done with isotype controls and/or conducted 
in lysates lacking the RBP of interest) can further 
increase specificity of peak calling. Comparison of 
the CLIP peaks with transcript abundance derived 
from matching RNA-seq experiments allows the 
discrimination of whether a binding event is merely 
a result of transcript abundance or a more specific 
interaction between the RBP and its target RNA. 
Several peak calling programs have been developed 
and include Piranha [56], CLIPper [57], PIPE-CLIP 
[58], Pyicos [59] that work with all CLIP variants, and 
PARalyzer [60] and wavClusteR that are specifically 
developed for PAR-CLIP analysis. For more details 
on the statistical models underlying these programs, 
we refer the readers to detailed reviews on this topic 
[41, 42].
4. Post-processing analyses: Following the identification 
of peaks, further analyses are typically conducted to 
identify the specific rules that may determine protein 
binding. For example, many studies generally assess 
what classes of RNAs and where within those tran-
scripts binding sites are located and whether there 
are distinct motifs within the binding sites. While the 
former analyses are done usually by custom scripts, 
programs such as MEME [61], HOMER [62] and 
cERMIT [63] are commonly used for motif discovery. 
Finally, binding sites derived from CLIP experiments 
can further be analyzed by programs that are com-
monly used in gene expression profiling experiments 
for gene ontology and pathway analyses.
Application of CLIP techniques in retrovirology
Novel insights into selective HIV‑1 genome packaging
All major steps of HIV-1 particle assembly are orches-
trated by the major structural protein, Gag [6]. Gag 
undergoes major changes in its subcellular localization, 
structure and oligomeric state during this process. Imme-
diately following its synthesis, Gag exists as a diffuse pool 
of monomers and low-order multimers in the cytosol, 
where it initially binds to the viral RNA genome [64, 
65]. Concurrent with binding to the plasma membrane 
Gag undergoes a major structural change and oligomer-
izes around the viral genome [65]. Following the release 
of immature particles from the host cell’s plasma mem-
brane, particles undergo maturation—Gag is subjected 
to several proteolytic cleavages, which liberates NC and 
other constituent domains. NC remains bound to the 
viral genome and condenses with it inside the remod-
eled conical capsid lattice. Thus, a crucial property of 
Gag is its ability to select two copies of the viral genome 
for packaging in the cytosol and remain bound to them 
through various subcellular settings and configurations.
The mechanism by which HIV-1 selectively packages a 
dimeric unspliced viral genome is based largely on prior 
Page 7 of 14Bieniasz and Kutluay Retrovirology  (2018) 15:35 
observations with simple retroviruses, as well as genetic 
studies and limited in  vitro data. Selective packaging of 
the HIV-1 genome is governed in part by binding of the 
nucleocapsid (NC) domain of Gag to a highly structured 
cis-acting packaging element, psi (Ψ), within the 5′ leader 
of the viral genome, composed of sequences in the unique 
5′ region (U5) and between the tRNA primer binding site 
(PBS) and the 5′ portion of the Gag open reading frame 
(ORF). However, disruption of Ψ only modestly decreases 
HIV-1 RNA encapsidation [66–68], and sequences out-
side Ψ can increase virion RNA levels and viral vector 
titers [69–73]. In addition, viral RNA is not necessary for 
particle assembly and cellular RNAs can be packaged in 
its absence [74, 75]. Thus, although several lines of evi-
dence have long indicated that sequences other than Ψ 
can contribute to genome packaging, determining the 
identities and features of these elements remained a chal-
lenge, due largely to lack of proper assays to study this 
process in cells.
Application of the CLIP methodology to the study of 
Gag-RNA interactions during different stages of particle 
assembly in cells revealed previously unanticipated rules 
of selective genome packaging [14]. First, nucleotide-res-
olution mapping of Gag binding to the HIV-1 genome in 
the cytosol revealed selective binding to sequences that 
coincide nearly precisely with a minimal element that can 
drive genome packaging. This minimal psi (Ψ) element 
adopts alternative structures, one of which favors genome 
packaging [76–78]. Second, in addition to Ψ, cytoplas-
mic Gag was bound to additional discrete elements on 
the viral RNA, including Rev Responsive Element (RRE), 
another highly structured region that mediates the 
export of HIV-1 RNAs from the nucleus. Although Gag-
RRE interactions appeared to be dispensable for genome 
packaging, a more recent study has implied a role for it 
in preventing Gag from moving away from the viral RNA 
genome in the cytosol [79]. Third, mapping of Gag binding 
sites within the cellular mRNAs revealed a striking con-
trast between the binding preference of cytosolic versus 
membrane-bound Gag; while cytosolic Gag preferentially 
bound to GU-rich motifs, A-rich mRNA sequences were 
found to be enriched in plasma membrane-bound mRNA 
molecules. Remarkably, the nucleotide composition of the 
cellular mRNA targets of Gag at the plasma membrane 
mirrored the unusual A-rich nucleotide composition of 
the HIV-1 genome [14]. Finally, upon proteolytic cleav-
age of Gag in mature virions, the NC binding preference 
reverted back to GU-rich mRNA sequences and discrete 
viral RNA elements including Ψ. Together, these findings 
suggest that upon binding of monomeric Gag to the viral 
genome through Ψ, multimerization-dependent changes 
in the RNA binding specificity of Gag may drive the selec-
tive packaging of the A-rich viral genome. In line with this 
model, a recent study has shown that longer segments of 
the Gag ORF, but not Ψ alone, can gradually increase the 
packaging of heterologous RNAs into virions [80]. Thus as 
part of the selective RNA packaging process, the role of 
Gag-Ψ interaction may be to nucleate further assembly of 
Gag oligomers on the viral genome [81].
HIV‑1 MA‑tRNA interactions
In addition to the NC domain, the matrix (MA) domain 
of Gag had long been suspected to bind RNA,  based 
largely on in  vitro assays [82–87]. The N-terminal basic 
amino acids of MA that are thought to bind RNA also 
mediate binding to cellular membranes [83, 88–92]. 
However, MA-RNA interaction has been thought to be 
fairly non-specific, and whether it actually occurs in cells 
could not be addressed until the application of the CLIP 
methodology. By releasing MA from Gag by Factor Xa 
protease-mediated cleavage as part of the CLIP proce-
dure, following UV-crosslinking of Gag-expressing cells, 
MA was bound to a specific set of tRNAs in the cytosol 
[36]. In fact, MA-tRNA interactions constituted the most 
frequent binding event between cytosolic Gag and RNA. 
Notably, MA-tRNA interaction was lost upon binding 
of Gag to the plasma membrane and RNase treatment 
of cell lysates expressing Gag led to significantly higher 
levels of membrane associated Gag [36]. Together, these 
findings suggested that occlusion of MA basic residues 
by specific tRNAs may target HIV-1 assembly to the 
plasma membrane and prevent nonproductive assembly 
on intracellular membranes. Alternatively, tRNA bind-
ing by MA may temporally regulate membrane bind-
ing and assembly [93]. Recent in vitro liposome binding 
assays also revealed that a specific set of RNAs, including 
Ψ, total yeast tRNA and  tRNAPro can inhibit Gag bind-
ing to negatively charged lipid membranes lacking PI(4, 
5)P2 [94]. Interestingly,  tRNALys, which was one of the 
most frequently bound to tRNAs by MA in cells [36], did 
not prevent Gag binding to liposomes [94]. As this study 
only tested the ability of in  vitro transcribed tRNAs in 
regulating Gag membrane binding, it remains to be seen 
whether tRNAs containing the complete set of post-tran-
scriptional modifications exhibit differences in MA bind-
ing in vitro.
In addition to regulation of Gag membrane bind-
ing, MA-tRNA interactions could have other func-
tions. An obvious possibility is regulation of viral and/
or host translation. As a result of the unusually A-rich 
nature of the HIV-1 genome [95–97], Ile, Lys, Glu and 
Val codons are overrepresented in the Gag and Pol ORFs 
[98]. Notably,  tRNALys,  tRNAGlu and  tRNAVal were found 
to be amongst the most frequently bound by MA, sug-
gesting the possibility of MA enhancing the transla-
tion of Gag and Pol by sequestering these specific set of 
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tRNAs. Alternatively, it is conceivable that by sequester-
ing tRNAs, MA could inhibit translation of host mRNAs 
whose products may block viral replication. Indeed, one 
report has suggested that interaction of MA with host 
translation elongation factors via a tRNA bridge could 
inhibit in  vitro translation [84]. It remains to be deter-
mined whether MA-tRNA interactions in a relevant 
infection setting can influence viral or host translation. 
Finally, it is possible that if not bound by tRNAs, the 
basic patch on MA may nonspecifically bind to the viral 
genome and even prevent the proper interaction of NC 
with the genome, which may inhibit subsequent steps 
of infection. In a similar scenario, MA binding to small 
RNAs might be a mechanism to avoid aggregation by a 
protein that has two distinct RNA binding domains and 
an intrinsic tendency to multimerize.
Role of IN‑RNA interactions in particle maturation
The morphological changes that occur during HIV-1 
particle maturation are often thought to be depend-
ent only on proteolytic cleavage of Gag. The cleaved CA 
domain of Gag forms the conical lattice within which 
the viral genome condenses, along with the cleaved NC 
domain of Gag as well as viral enzymes integrase (IN) 
and reverse transcriptase (RT), cleavage products of the 
Pol polyprotein. However, more than two decades ago, 
mutational studies of the HIV-1 IN indicated that it may 
also play an active role in proper particle maturation 
[99–110]. In particular, a set of mutations referred to as 
Class II IN mutations, were shown to lead to the forma-
tion of morphologically aberrant “eccentric” particles, in 
which the viral ribonucleoproteins complexes (vRNPs) 
are mislocalized outside the conical CA lattice [101, 103, 
111]. Although IN is known to bind DNA through sev-
eral charged residues scattered throughout the protein 
(reviewed in [112]) and can bind to RNA in  vitro with 
some specificity [113], why and how mutations within 
IN would specifically lead to mislocalization of vRNPs in 
virions remained enigmatic.
The recent development of allosteric integrase inhibi-
tors (ALLINIs) reignited research in this area. While 
ALLINIs were initially developed to target IN binding to 
the cellular cofactor LEDGF, it was later shown that these 
compounds primarily act during particle maturation and 
lead to morphological aberrations in particles similar to 
those induced by the aforementioned Class II IN muta-
tions [114–119]. Biochemical analysis of IN in vitro and 
in virions revealed that ALLINIs induce aberrant IN 
multimerization [103, 111, 120–123] through catalytic 
core domain–C-terminal domain interactions at the 
dimer–dimer interface [116]. By employing CLIP and 
complementary in vitro approaches, recent studies have 
shown that low-order multimers of IN binds to distinct 
structured elements on the viral genome, including TAR, 
with high affinity [13]. Notably, while ALLINIs indirectly 
block these interactions by inducing IN oligomerization, 
mutations of basic amino acids within the C-terminal 
domain of IN can abolish IN-RNA binding directly with-
out altering the multimeric state of IN. Inhibition of IN-
RNA interactions leads to mislocalization vRNPs and IN 
outside the conical capsid core [124]. Surprisingly, CLIP 
experiments reveal that the pattern of NC binding on 
the vRNA genome seems to be unaffected by IN muta-
tions or ALLINIs, despite the mislocalization of vRNPs 
in eccentric particles [124]. Together, these aberrations in 
virion morphology are accompanied by premature deg-
radation of vRNPs and IN, and spatial separation of RT 
from vRNPs, explaining the early reverse transcription 
block of these particles in target cells [124]. Thus, CLIP 
has been key in unveiling the key role of IN-RNA inter-
actions during virion morphogenesis that ensure the cor-
rect localization of core components inside the CA lattice 
during particle maturation.
Incorporation of APOBEC3 proteins into virions
While viral RNAs contain sequence and structural ele-
ments that regulate key steps in HIV-1 replication, they 
can also be recognized by host defense mechanisms. 
Infiltration of the host APOBEC3 (A3) proteins into virus 
particles by binding viral RNAs is a prime example of this 
process. A3 proteins are a family of cytidine deaminases 
that inhibit the replication of a broad range of viruses 
and retroelements (reviewed in [125, 126]). A3s inhibit 
replication in two ways. One mechanism involves the 
deamination of cytidines to uridines in (–) strand DNA 
during reverse transcription, resulting in the accumula-
tion dG-to-dA mutations on the coding strand [127–130] 
and lethal hypermutation. Additionally, A3 proteins have 
been shown to induce a deamination-independent block, 
by binding to reverse transcriptase and inhibiting reverse 
transcription [131–135]. Packaging of A3 proteins into 
HIV-1 virions is required for their antiviral activity and 
depends on the NC domain of Gag and its associated 
RNA [136–141]. A3 proteins appear to be promiscuous 
RNA binding proteins and it has been difficult to deter-
mine whether they selectively target viral or cellular 
RNAs to infiltrate into particles. For example, there is 
evidence to indicate that viral genome [142], 7SL RNA, a 
cellular RNA that is normally part of the signal recogni-
tion particle and is enriched in retroviral particles [143], 
or both cellular and viral RNAs [140, 141] can mediate 
packaging of A3G into particles. As many of these stud-
ies largely relied only on genetic assays, whether A3 
proteins exhibit any preference towards a specific set of 
RNAs, or sequence features within them in a relevant 
setting remained unknown. Nevertheless, the presence 
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of a discrete RNA binding domain in A3G implies some 
level of selectivity in RNA binding, much like other RBPs 
[144, 145].
Three recent studies employing CLIP have provided 
insight into the RNA-binding properties of several A3 
proteins in infected cells and in virions [146, 147]. The 
earlier iCLIP-based study indicated that although the 
viral genome is enriched amongst A3F and A3G-bound 
RNAs, a diverse set of RNAs could drive the incorpora-
tion of A3F and A3G into virions [146]. A subsequent 
PAR-CLIP-based study confirmed some of these findings 
in that A3 proteins were shown to bind similar classes of 
cellular RNAs and HIV-1 RNA was bound preferentially 
over cellular RNAs in infected cells. However, the PAR-
CLIP approach provided a higher resolution assessment 
of A3-RNA interactions in cells, likely due to the ability 
to more accurately identify the site of crosslinking. Most 
importantly, detailed analysis of A3 binding sites revealed 
that the A3 proteins partly mimic the RNA-binding 
specificity of NC, in that they target RNA sequences 
that are G-rich and A-rich [147]. This model provides 
some explanation of how A3 proteins are incorporated 
efficiently into virions in the presence of a vast excess 
of cellular RNA molecules. This model invokes a bias in 
the binding of A3 proteins to RNA molecules of a given 
sequence composition, as a way of maintaining broad 
RNA binding specificity, while removing the need to 
occupy all mRNA sequences present in an infected cell. 
One recent study, the first to reveal a crystal structure of 
an A3 protein in complex with an RNA showed that the 
A3H protein has a particular propensity to bind to seven-
nucleotide duplexes, in a manner that was independent 
of the nucleotide sequences forming the duplexes  [148]. 
Accompanying CLIP experiments showed that the sites 
in the HIV-1 genome to which A3H was most frequently 
bound were invariably predicted to contain 7nt duplexes.
Role of zinc finger antiviral protein (ZAP) in imposing 
compositional bias on viral genomes
The genomes of vertebrates are marked  with a paucity 
of CG dinucleotides [149], a feature that is well under-
stood to have been caused by the action of CG-specific 
DNA methyl transferases and methyl-cytosine deamina-
tion, over hundreds of millions of years. More mysteri-
ously, inspection of the composition of the genomes of 
RNA viruses in vertebrates, reveal that they mimic this 
CG-poor state, even though they are  not substrates for 
DNA methyl transferases [150–152]. Recent work, in 
the context of HIV-1 has shown that the paucity of CG 
dinucleotides is essential for viral replication, and that 
the appearance of too many CG dinucleotides in the viral 
genome causes cytoplasmic depletion of viral RNA [153]. 
The apparently destabilizing effect of CG dinucleotides 
was cumulative, and found to be induced by CG dinucle-
otides in both translated portions of an mRNA and also 
in untranslated exons. Further experiments showed that 
zinc finger antiviral protein (ZAP) [154] a protein that 
encodes four CCCH zinc fingers in is N-terminal domain 
is essential the for mediating the deleterious effects of CG 
dinucleotides. Indeed, HIV-1 mutants containing seg-
ments whose CG-content mimicked  a random nucleo-
tide sequence could not replicate in unmanipulated cells 
containing an intact ZAP gene, but could replicate with 
wild-type kinetics in cells rendered ZAP-deficient by 
CRISPR-Cas9 editing [153].
While previous studies had shown that ZAP had anti-
viral activity against a number of RNA viruses, several 
conventional techniques could not identify a common 
sequence motif or RNA feature that could explain how 
ZAP was able to specifically target viral RNA sequences 
[154, 155]. RNA elements that could confer sensitivity to 
ZAP when inserted into a reporter RNA were large, lead-
ing to the proposal that a specific tertiary structure con-
stituted a ZAP recognition site. However, RNA elements 
that conferred sensitivity to ZAP did so in both orienta-
tions [156], effectively refuting these models. CLIP exper-
iments showed unambiguously that ZAP binds directly 
and selectively to RNA elements that contain CG dinu-
cleotides, but exhibits no preferential binding to RNA 
elements containing GC or any other dinucleotide [153]. 
Interestingly, these results suggest that ZAP arose to 
exploit a compositional difference between host mRNAs 
and RNAs from viruses have high CG content. However, 
the dinucleotide composition of HIV-1, appears to have 
adapted to evade ZAP and it is possible that ZAP has 
driven the purging of CG dinucleotides from a range of 
RNA viruses.
Identification of  m6A marks on HIV‑1 RNAs
Like proteins and DNA, RNA can undergo a number 
of chemical modifications that subsequently affect its 
metabolism, function and localization. While tRNAs and 
rRNAs are subjected to the most diverse set of modifi-
cations, recent transcriptome-wide studies revealed the 
presence of numerous mRNAs modifications [157–162]. 
Methylation of adenosine at the N6 position  (m6A) is the 
most prevalent of these and has been proposed to regu-
late several aspects of RNA metabolism, including splic-
ing, nuclear export, localization, stability and translation 
[163].  m6A modification is catalyzed by a nuclear “writer” 
protein complex, composed of two methyltransferase-
like enzymes, METTL3 and MTTL4, and their cofac-
tor Wilms tumor 1-associated protein (WTAP). This 
modification can be reversed by two RNA demethylases, 
or ‘‘erasers’’, ALKBH5 (a-ketoglutamarate-dependent 
dioxygenase homolog 5) and FTO (fat mass and obesity 
Page 10 of 14Bieniasz and Kutluay Retrovirology  (2018) 15:35 
associated).  m6A-modifications on mRNAs can be bound 
by three related cytosolic ‘‘reader’’ proteins called YTH-
domain containing family 1 (YTHDF1), YTHDF2, and 
YTHDF3. Exactly how binding of these proteins on 
modified nucleotides regulate mRNA metabolism is cur-
rently unknown. Nonetheless,  m6A modifications can 
be found on mRNAs of diverse viruses that replicate in 
the nucleus, including SV40 [164], adenovirus [165, 166], 
influenza A virus [167] as well as retroviruses such as 
avian sarcoma virus [168] and Rous sarcoma virus [169, 
170]. Until recently, whether HIV-1 mRNAs contained 
 m6A modifications and how this affected virus replica-
tion was not known.
Three recent studies have addressed this question by 
immunoprecipitating methylated HIV-1 RNAs from 
infected cells using a  m6A-specific antibody followed by 
high throughput sequencing of the immunoprecipitated 
mRNAs [171–173]. Strikingly, there was virtually no 
overlap in the  m6A sites identified in these independent 
studies. This lack of consistency can in part be explained 
by the different approaches taken. The first published 
study that has utilized a RIP-seq approach, in which 
 m6A-modified RNAs were immunoprecipitated from 
cell lysates and sequenced, found  m6A modifications 
throughout the viral genome [172]. In contrast, a later 
study, which included a PAR-CLIP-based crosslinking 
step following immunoprecipitation of  m6A-modified 
RNAs, found that the  m6A modifications were exclusively 
localized within the viral 3′ UTRs [171]. Importantly, par-
allel YTHDF PAR-CLIP experiments conducted in this 
latter study revealed binding sites at or near the modified 
nucleotides, reinforcing the findings from  m6A-specific 
immunoprecipitations [171]. A third study similarly cou-
pled YTHDF HITS-CLIP with  m6A-seq [173] and identi-
fied putative modification sites within 3′ and 5′ UTRs of 
HIV-1 mRNAs. Notably, none of these sites overlapped 
with those identified in the former studies. Thus, while 
CLIP methodologies have been highly instrumental in 
identification of  m6A sites on HIV-1 RNAs, cross-valida-
tion of reagents (i.e. cell lines, viruses,  m6A antibodies) 
and methods (i.e.  m6A-seq, PAR- vs. HITS-CLIP) will be 
necessary to reach to a consensus in future studies.
Conclusions
Application of the CLIP methods to questions in retro-
virology will undoubtedly continue to increase, given the 
large number of RBPs that are known and continuing to 
emerge as key regulators of retroviral replication. Several 
poorly explored areas in retrovirology will benefit from 
these approaches. One of the immediate applications of 
this methodology will be in determining how the alterna-
tive splicing of HIV-1 transcripts is regulated by cellular 
hnRNP and SR splicing-regulatory proteins. Although 
the families of hnRNP and SR proteins constitute more 
than 50 proteins, only a few have been shown to play roles 
in HIV-1 RNA splicing. In addition, none of the stud-
ies performed to date determined where on viral RNAs 
these proteins bind. Instead, in  vitro splicing reporters 
and genetic assays were used, which are prone to arte-
facts. Another exciting area of research where CLIP 
and related methodologies may make a major impact is 
the sensing of viral nucleic acids in infected cells. HIV-1 
infection induces high levels of interferon and other 
cytokines during the acute phase of infection, suggest-
ing that viral nucleic acids are sensed in infected cells. 
While a few isolated studies indicated that viral reverse 
transcription products or RNA elements can be sensed 
in certain settings, it remains to be determined what fea-
tures of viral nucleic acids are sensed and whether viral 
RNA or DNA elicits an inflammatory response. While A3 
proteins provide a good example of how viral RNAs can 
be targeted by antiviral host proteins, it is plausible that 
many other cellular proteins that can recognize and tar-
get viral RNAs. CLIP will be a key tool in unveiling novel 
cellular proteins that participate at the HIV-1-host inter-
face. Finally, although CLIP has so far only been applied 
to HIV-1 biology, it will certainly find broad applica-
tions in retrovirology and virology more generally as the 
methods and next-generation sequencing becomes more 
accessible.
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